Shkreli's arrest may have implications for the development of certain drug patents it holds. On Sunday, Moffitt Cancer Center released a statement saying it had suspended clinical trials of a drug held by KaloBios, another company run by Shkreli.
Moffitt "was among several participating sites of the clinical trial 'Study of KB003 in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)'funded by KaloBios," the center said in an emailed statement to CNBC.
"The biopharmaceutical company holds ownership of the clinical trial and KB003 drug. Moffitt has suspended this clinical trial indefinitely pending the outcome of the investigation of KaloBios' CEO, Martin Shkreli," it added.